Sep 10, 2020 / 03:40PM GMT
Neena Marie Bitritto-Garg - Citigroup Inc., Research Division - VP & Analyst
All right. So good morning, everyone. Thank you for joining Citi's 15th Annual Biopharma Conference. I'm Neena Bitritto-Garg. I'm one of the Smid cap biotech analyst here at Citi. For our fireside chat, I'm pleased to be joined by the team from Alector. I have with me today Shehnaaz Suliman, President and COO; Robert Paul, Chief Medical Officer; and Sabah Oney, Chief Business Officer.
So just to start off, Shehnaaz, if you want to talk a little bit about just kind of the concept of neuroimmunology and how it's differentiated from some of the previous approaches that have been taken in neurodegenerative diseases, that would be great.
Questions and Answers:
Shehnaaz Suliman - Alector, Inc. - President & COOThank you, Neena, and it's great to be with everyone today. We're pioneering a completely new approach to treating brain disorders, which we call immuno-neurology, which integrates immunology and neuroscience and genetics to develop therapeutics